Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Mol Cancer Ther Retrieve available abstracts of 20 articles: HTML format Text format

Single Articles

September 2018
1. MOCHIZUKI S, Shimoda M, Abe H, Miyamae Y, et al
   Selective inhibition of ADAM28 suppresses lung carcinoma cell growth and metastasis.
   Mol Cancer Ther. 2018 Sep 6. pii: 1535-7163.MCT-17-1198.
   PubMed     Text format     Abstract available
   
   
   July 2018
2. SUDA K, Murakami I, Yu H, Kim J, et al
   CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer.
   Mol Cancer Ther. 2018 Jul 26. pii: 1535-7163.MCT-17-1279.
   PubMed     Text format     Abstract available
   
   
   June 2018
3. SHIN DH, Jo JY, Han JY
   Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer.
   Mol Cancer Ther. 2018 Jun 29. pii: 1535-7163.MCT-17-1178.
   PubMed     Text format     Abstract available
   
   
   
4. NJATCHA C, Farooqui M, Kornberg A, Johnson DE, et al
   STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
   Mol Cancer Ther. 2018 Jun 11. pii: 1535-7163.MCT-17-1194.
   PubMed     Text format     Abstract available
   
   
   April 2018
5. BOCKORNY B, Rusan M, Chen W, Liao RG, et al
   RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
   Mol Cancer Ther. 2018 Apr 13. pii: 1535-7163.MCT-17-0464.
   PubMed     Text format     Abstract available
   
   
   February 2018
6. HIRANO T, Yasuda H, Hamamoto J, Nukaga S, et al
   Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.
   Mol Cancer Ther. 2018 Feb 21. pii: 1535-7163.MCT-17-1033.
   PubMed     Text format     Abstract available
   
   
   October 2017
7. YAMADA T, Amann JM, Tanimoto A, Taniguchi H, et al
   Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations.
   Mol Cancer Ther. 2017 Oct 27. pii: molcanther.0146.2017.
   PubMed     Text format     Abstract available
   
   
   August 2017
8. AKENO N, Reece AL, Callahan M, Miller AL, et al
   Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
   Mol Cancer Ther. 2017 Aug 28. pii: molcanther.0353.2017.
   PubMed     Text format     Abstract available
   
   
   
9. WATANABE S, Yoshida T, Kawakami H, Takegawa N, et al
   T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer.
   Mol Cancer Ther. 2017 Aug 24. pii: molcanther.0351.2017.
   PubMed     Text format     Abstract available
   
   
   July 2017
10. SHIEN K, Papadimitrakopoulou VA, Ruder D, Behrens C, et al
    JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.
    Mol Cancer Ther. 2017 Jul 20. pii: molcanther.0148.2016.
    PubMed     Text format     Abstract available
    
    
    May 2017
11. GAUTAM J, Ku JM, Regmi SC, Jeong H, et al
    Dual inhibition of NOX2 and receptor tyrosine kinase by BJ-1301 enhances anticancer therapy efficacy via suppression of autocrine stimulatory factors in lung cancer.
    Mol Cancer Ther. 2017 May 23. pii: molcanther.0915.2016.
    PubMed     Text format     Abstract available
    
    
    
12. RAIMBOURG J, Joalland MP, Cabart M, de Plater L, et al
    Sensitization of EGFR wild-type non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib.
    Mol Cancer Ther. 2017 May 18. pii: molcanther.0075.2017.
    PubMed     Text format     Abstract available
    
    
    
13. ROSS KC, Andrews AJ, Marion CD, Yen TJ, et al
    Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells.
    Mol Cancer Ther. 2017 May 12. pii: molcanther.0798.2016.
    PubMed     Text format     Abstract available
    
    
    
14. LAM LT, Lin X, Faivre EJ, Yang Z, et al
    Vulnerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors.
    Mol Cancer Ther. 2017 May 3. pii: molcanther.0459.2016.
    PubMed     Text format     Abstract available
    
    
    
15. CHATTERJEE S, Huang EH, Christie I, Kurland BF, et al
    Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.
    Mol Cancer Ther. 2017;16:793-804.
    PubMed     Text format     Abstract available
    
    
    April 2017
16. MANUEL-MANRESA P, Korrodi-Gregorio L, Hernando E, Villanueva A, et al
    Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0752.2016.
    PubMed     Text format     Abstract available
    
    
    
17. GIMENEZ-XAVIER P, Pros E, Bonastre E, Moran S, et al
    Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0104.2017.
    PubMed     Text format     Abstract available
    
    
    
18. SALGIA R
    MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
    Mol Cancer Ther. 2017;16:555-565.
    PubMed     Text format     Abstract available
    
    
    March 2017
19. WOO JK, Jang JE, Kang JH, Seong JK, et al
    Lectin, galactoside-binding soluble 3 binding protein promotes 17-N-Allylamino-17-demethoxygeldanamycin resistance through PI3K/Akt pathway in lung cancer cell line.
    Mol Cancer Ther. 2017 Mar 23. pii: molcanther.0574.2016.
    PubMed     Text format     Abstract available
    
    
    January 2017
20. HAAK AJ, Appleton KM, Lisabeth EM, Misek SA, et al
    Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.
    Mol Cancer Ther. 2017;16:193-204.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: